After TNF-α/NF-κB1 being successfully abrogated by BAY 11–7082, anti-angiogenic treatment-induced CD47 upregulation was diminished in NSCLC tumors and produced increased anti-tumor effect (Fig. 3a and b, Additional file 6: Figure S6). This evidence concerns the gene TNF and non-small cell lung carcinoma.